
Hisashi Yamanaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1654808/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication. Modern Rheumatology, 2023, 33, 21-35.	1.8	35
2	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 74-86.	1.8	11
3	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 313-322.	1.8	7
4	Factors associated with frailty in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study. Clinical Rheumatology, 2022, 41, 405-410.	2.2	8
5	A simple screening test to assess risk of falls in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study. Modern Rheumatology, 2021, 31, 506-509.	1.8	2
6	Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data. Modern Rheumatology, 2021, 31, 261-269.	1.8	41
7	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis – A systematic review and meta-analysis. Modern Rheumatology, 2021, 31, 61-69.	1.8	8
8	Adherence to denosumab for the treatment of osteoporosis in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study. Modern Rheumatology, 2021, 31, 510-513.	1.8	2
9	Efficacy and Safety of E6011, an Antiâ€Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase II Study. Arthritis and Rheumatology, 2021, 73, 587-595.	5.6	17
10	Polypharmacy, declined walking speed, bent back, and disability associated with a history of falls in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study. Modern Rheumatology, 2021, 31, 764-767.	1.8	5
11	Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiology and Drug Safety, 2021, 30, 157-168.	1.9	18
12	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Modern Rheumatology, 2021, 31, 34-41.	1.8	14
13	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology, 2021, 31, 783-789.	1.8	11
14	Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings. Modern Rheumatology, 2021, 31, 790-795.	1.8	2
15	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. Journal of Rheumatology, 2021, 48, 1663-1671.	2.0	10
16	Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. Annals of the Rheumatic Diseases, 2021, 80, 1483-1490.	0.9	22
17	Vitamin D deficiency is a risk factor for new fractures in Japanese postmenopausal women with rheumatoid arthritis: results from the IORRA cohort study. Archives of Osteoporosis, 2021, 16, 119.	2.4	8
18	Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. BMC Pediatrics, 2021, 21, 581.	1.7	0

#	Article	IF	CITATIONS
19	Age and female gender associated with periodontal disease in Japanese patients with rheumatoid arthritis: Results from self-reported questionnaires from the IORRA cohort study. Modern Rheumatology, 2020, 30, 465-470.	1.8	7
20	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study. Modern Rheumatology, 2020, 30, 442-449.	1.8	2
21	Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Modern Rheumatology, 2020, 30, 941-947.	1.8	45
22	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology, 2020, 30, 424-433.	1.8	1
23	Updated version of Japanese Childhood Health Assessment Questionnaire (CHAQ). Modern Rheumatology, 2020, 30, 905-909.	1.8	4
24	A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options. Modern Rheumatology, 2020, 30, 1-6.	1.8	83
25	A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2020, 7, 149-163.	2.3	11
26	The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis. Clinical Rheumatology, 2020, 39, 841-845.	2.2	3
27	Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. BMC Pediatrics, 2020, 20, 481.	1.7	6
28	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 316-324.	1.9	4
29	Non-increased risk of thrombosis by steroid pulse therapy in patients with lupus nephritis from the Japanese health insurance database. Thrombosis Research, 2020, 190, 86-88.	1.7	1
30	Factors associated with decreasing serum 25(OH)D among Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study. Modern Rheumatology, 2019, 29, 430-435.	1.8	7
31	Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance. Modern Rheumatology, 2019, 29, 737-746.	1.8	5
32	Four cases of HLA-A*26(+)/B*51(â^') intestinal Behçet's disease without abdominal symptoms. Modern Rheumatology Case Reports, 2019, 3, 38-44.	0.7	0
33	Juvenile idiopathic arthritis with no complaints of joint pain in early childhood. Modern Rheumatology Case Reports, 2019, 3, 10-13.	0.7	0
34	Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naÃ⁻ve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Modern Rheumatology, 2019, 29, 572-580.	1.8	7
35	Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Annals of the Rheumatic Diseases, 2019, 78, 1480-1487.	0.9	36
36	Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibodyâ€associated vasculitis, using a Japanese health insurance database. International Journal of Rheumatic Diseases, 2019, 22, 1978-1984.	1.9	16

#	Article	IF	CITATIONS
37	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.9	72
38	A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week). Immunological Medicine, 2019, 42, 99-102.	2.6	0
39	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Four–Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	5.6	64
40	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.9	25
41	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq1 1 (2019, 78, 899-907.).784314 rgB	T /Overlock 105
42	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asiaâ€Pacific region: Postâ€hoc analyses of pooled clinical study data. International Journal of Rheumatic Diseases, 2019, 22, 1094-1106.	1.9	12
43	Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases. JMA Journal, 2019, 3, 20-28.	0.8	2
44	Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 284-286.	0.9	3
45	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Modern Rheumatology, 2019, 29, 747-755.	1.8	17
46	KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. Modern Rheumatology, 2019, 29, 625-632.	1.8	18
47	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. Modern Rheumatology, 2019, 29, 756-766.	1.8	10
48	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology, 2019, 29, 306-313.	1.8	3
49	Hypouricaemic effects of yoghurt containing <i>Lactobacillus gasseri</i> PA-3 in patients with hyperuricaemia and/or gout: A randomised, double-blind, placebo-controlled study. Modern Rheumatology, 2019, 29, 146-150.	1.8	43
50	No increased risk of herpes zoster in TNF inhibitor and nonâ€TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. International Journal of Rheumatic Diseases, 2018, 21, 1670-1677.	1.9	18
51	Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody–positive Cases. Journal of Rheumatology, 2018, 45, 947-955.	2.0	14
52	Capillary abnormalities observed by nailfold video-capillaroscopy in Japanese patients with systemic sclerosis. Modern Rheumatology, 2018, 28, 1066-1068.	1.8	1
53	<i>HLA-DRB1</i> Analysis Identified a Genetically Unique Subset within Rheumatoid Arthritis and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies. Journal of Rheumatology, 2018, 45, 470-480.	2.0	6
54	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Modern Rheumatology, 2018, 28, 941-949.	1.8	3

#	Article	IF	CITATIONS
55	Design characteristics of the Corrona Japan rheumatoid arthritis registry. Modern Rheumatology, 2018, 28, 95-100.	1.8	2
56	Productivity loss of Japanese patients with rheumatoid arthritis – A cross-sectional survey. Modern Rheumatology, 2018, 28, 482-489.	1.8	24
57	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. Modern Rheumatology, 2018, 28, 9-16.	1.8	63
58	Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. Modern Rheumatology, 2018, 28, 461-467.	1.8	15
59	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. Modern Rheumatology, 2018, 28, 770-779.	1.8	5
60	Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the Rheumatic Diseases, 2018, 77, 270-276.	0.9	76
61	Integration of genetics and miRNA–target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Research, 2018, 46, 11898-11909.	14.5	39
62	Neurodevelopmental disorders associated with juvenile fibromyalgia. Pediatrics International, 2018, 60, 1034-1035.	0.5	3
63	Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort. PLoS ONE, 2018, 13, e0202427.	2.5	28
64	Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases, 2018, 72, 798-810.	1.9	244
65	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases, 2018, 77, 1268-1275.	0.9	43
66	Genetic differences between type 1 diabetes with and without other autoimmune diseases. Diabetes/Metabolism Research and Reviews, 2018, 34, e3023.	4.0	4
67	Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody. Case Reports in Rheumatology, 2018, 2018, 1-5.	0.6	1
68	Progressive destructive bronchiolectasis followed by appearance of multiple pulmonary cystic lesions mimicking honeycombing in a patient with rheumatoid arthritis. Modern Rheumatology Case Reports, 2018, 2, 14-19.	0.7	1
69	Tuberculosis-immune reconstitution inflammatory syndrome associated with juvenile enthesitis-related arthritis under treatment of adalimumab. Modern Rheumatology Case Reports, 2018, 2, 149-152.	0.7	1
70	Colonoscopy was useful for the diagnosis and the guidance of treatment escalation/de-escalation in a refractory case of lupus colitis. Modern Rheumatology Case Reports, 2018, 2, 30-32.	0.7	1
71	IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand. Central-European Journal of Immunology, 2018, 43, 148-154.	1.2	16
72	Successful delivery in a patient with clinically amyopathic dermatomyositis during pregnancy despite first-trimester acute exacerbation of interstitial lung disease. Modern Rheumatology, 2017, 27, 364-368.	1.8	7

#	Article	IF	CITATIONS
73	Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. Journal of Bone and Mineral Metabolism, 2017, 35, 344-350.	2.7	14
74	Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan. Modern Rheumatology, 2017, 27, 924-929.	1.8	6
75	Survey of attitudes of non-pediatric rheumatologists among councilors of the Japan College of Rheumatology regarding transitional care. Modern Rheumatology, 2017, 27, 1047-1050.	1.8	9
76	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases, 2017, 76, 1348-1356.	0.9	36
77	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Clinical Rheumatology, 2017, 36, 1237-1245.	2.2	23
78	Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2017, 44, 147-153.	2.0	7
79	Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nature Genetics, 2017, 49, 1120-1125.	21.4	130
80	Genetic landscape of interactive effects of <i>HLA-DRB1</i> alleles on susceptibility to ACPA(+) rheumatoid arthritis and ACPA levels in Japanese population. Journal of Medical Genetics, 2017, 54, 853-858.	3.2	3
81	Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis. Rheumatology International, 2017, 37, 1871-1878.	3.0	11
82	Systemic lupus erythematosus associated with RASopathy. Modern Rheumatology Case Reports, 2017, 1, 94-98.	0.7	7
83	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	3.8	25
84	The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice. Modern Rheumatology, 2017, 27, 430-434.	1.8	3
85	Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Modern Rheumatology, 2017, 27, 227-236.	1.8	13
86	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Modern Rheumatology, 2017, 27, 237-245.	1.8	54
87	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology, 2017, 27, 217-226.	1.8	26
88	RANK Expression and Osteoclastogenesis in Human Monocytes in Peripheral Blood from Rheumatoid Arthritis Patients. BioMed Research International, 2016, 2016, 1-6.	1.9	11
89	Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts. BioMed Research International, 2016, 2016, 1-7.	1.9	6
90	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	3.4	48

#	Article	IF	CITATIONS
91	Tonsillectomy to Effectively Treat a Patient with Behçet's Disease. Internal Medicine, 2016, 55, 515-517.	0.7	1
92	Response to: â€~Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossiniet al. Annals of the Rheumatic Diseases, 2016, 75, e71-e71.	0.9	2
93	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Annals of the Rheumatic Diseases, 2016, 75, 1917-1923.	0.9	81
94	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.9	18
95	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1â€year outcomes of the HOPEFUL-2 study. RMD Open, 2016, 2, e000189.	3.8	21
96	A twin study of rheumatoid arthritis in the Japanese population. Modern Rheumatology, 2016, 26, 685-689.	1.8	32
97	Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 836-843.	1.8	9
98	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (<i>D</i> enosumab) in patients with <i>R</i> heumato <i>I</i> d arthritis on methotrexate to <i>V</i> alidate inhibitory effect on bone <i>E</i> rosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 983-990.	0.9	157
99	Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. American Journal of Human Genetics, 2016, 99, 366-374.	6.2	68
100	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatology and Therapy, 2016, 3, 129-141.	2.3	3
101	Erythematosus plaques with macrophage infiltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus. Modern Rheumatology, 2016, 26, 956-957.	1.8	6
102	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 491-498.	1.8	80
103	Association between serum vitamin D level and history of falls in elderly Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 460-462.	1.8	9
104	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.9	16
105	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Modern Rheumatology, 2016, 26, 15-23.	1.8	53
106	Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics. Journal of Rheumatology, 2016, 43, 738-744.	2.0	7
107	<i>Post-hoc</i> analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Modern Rheumatology, 2016, 26, 473-480.	1.8	9
108	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 2016, 26, 651-661.	1.8	24

#	Article	IF	CITATIONS
109	Longer operative time is the risk for delayed wound healing after forefoot surgery in patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 211-215.	1.8	16
110	The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach. Modern Rheumatology, 2016, 26, 175-179.	1.8	10
111	Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database. Modern Rheumatology, 2016, 26, 40-45.	1.8	19
112	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases, 2016, 75, 75-83.	0.9	94
113	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. Modern Rheumatology. 2016. 26. 481-490.	1.8	13
114	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. Modern Rheumatology, 2016, 26, 323-330.	1.8	6
115	Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures. Rheumatology International, 2016, 36, 213-219.	3.0	14
116	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1354-1362.	3.4	26
117	An Association Between Amino Acid Position 74 of HLA–DRB1 and Anti–Citrullinated Protein Antibody Levels in Japanese Patients With Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2038-2045.	5.6	15
118	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and Drug Safety, 2015, 24, 1121-1132.	1.9	6
119	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	3.4	16
120	Painless lumps in the proximal interphalangeal joints in trichoâ€rhinoâ€phalangeal syndrome type 1. Pediatrics International, 2015, 57, 507-508.	0.5	0
121	Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 3113-3123.	5.6	25
122	Childhoodâ€Onset Antiâ€Ku Antibodyâ€Positive Generalized Morphea with Polymyositis: A Japanese Case Study. Pediatric Dermatology, 2015, 32, e224-5.	0.9	4
123	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Modern Rheumatology, 2015, 25, 11-20.	1.8	11
124	Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Modern Rheumatology, 2015, 25, 528-533.	1.8	3
125	Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Modern Rheumatology, 2015, 25, 350-357.	1.8	11
126	Neurocognitive Impairment in Corticosteroid-naive Patients with Active Systemic Lupus Erythematosus: A Prospective Study. Journal of Rheumatology, 2015, 42, 441-448.	2.0	23

#	Article	IF	CITATIONS
127	Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology, 2015, 25, 503-513.	1.8	16
128	Postoperative complications in patients with rheumatoid arthritis using a biological agent – A systematic review and meta-analysis. Modern Rheumatology, 2015, 25, 672-678.	1.8	33
129	Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Modern Rheumatology, 2015, 25, 558-561.	1.8	23
130	Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Modern Rheumatology, 2015, 25, 43-49.	1.8	13
131	Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clinical Rheumatology, 2015, 34, 441-449.	2.2	48
132	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2015, 25, 817-824.	1.8	69
133	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Modern Rheumatology, 2015, 25, 514-521.	1.8	109
134	Construct validity, reliability, response rate, and association with disease activity of the quick disabilities of the arm, shoulder and hand questionnaire in the assessment of rheumatoid arthritis. Modern Rheumatology, 2015, 25, 241-245.	1.8	16
135	Brief Report: Takayasu Arteritis and Ulcerative Colitis: High Rate of Coâ€Occurrence and Genetic Overlap. Arthritis and Rheumatology, 2015, 67, 2226-2232.	5.6	102
136	Brief Report: Main Contribution of DRB1*04:05 Among the Shared Epitope Alleles and Involvement of DRB1 Amino Acid Position 57 in Association With Joint Destruction in Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1744-1750.	5.6	23
137	Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study. Modern Rheumatology, 2015, 25, 373-378.	1.8	27
138	Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Modern Rheumatology, 2015, 25, 779-783.	1.8	10
139	Effect of Smoking on Remission Proportions Differs Between Male and Female Patients with Rheumatoid Arthritis: A Study Based on the IORRA Survey. Journal of Rheumatology, 2015, 42, 1083-1089.	2.0	12
140	Long-term outcome of 114 adult JIA patients in a non-pediatric rheumatology institute in Japan. Modern Rheumatology, 2015, 25, 62-66.	1.8	3
141	Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis:post hoctime-course analysis of an all-case PMS in Japan. Modern Rheumatology, 2015, 25, 495-502.	1.8	4
142	Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis. Clinical Immunology, 2015, 161, 333-338.	3.2	14
143	Association between a C8orf13–BLK Polymorphism and Polymyositis/Dermatomyositis in the Japanese Population: An Additive Effect with STAT4 on Disease Susceptibility. PLoS ONE, 2014, 9, e90019.	2.5	16
144	An Osteoprotegerin Gene Polymorphism Is Associated with an Increased Risk of Hip Fracture in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Observational Cohort Study. PLoS ONE, 2014, 9, e104587.	2.5	7

#	Article	IF	CITATIONS
145	Experimental immunology AÂnovel peptide from TCTA protein inhibits proliferation of fibroblast-like synoviocytes of rheumatoid arthritis patients. Central-European Journal of Immunology, 2014, 4, 468-470.	1.2	3
146	Quantitative analysis with advanced compensated polarized light microscopy on wavelength dependence of linear birefringence of single crystals causing arthritis. Journal Physics D: Applied Physics, 2014, 47, 285402.	2.8	5
147	New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study. Journal of Neurology, 2014, 261, 2150-2158.	3.6	16
148	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 552-560.	1.8	40
149	Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Modern Rheumatology, 2014, 24, 33-40.	1.8	124
150	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Modern Rheumatology, 2014, 24, 399-404.	1.8	15
151	Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan. Journal of Rheumatology, 2014, 41, 15-23.	2.0	174
152	Recent Trends in Orthopedic Surgery Aiming to Improve Quality of Life for Those with Rheumatoid Arthritis: Data from a Large Observational Cohort. Journal of Rheumatology, 2014, 41, 862-866.	2.0	35
153	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Modern Rheumatology, 2014, 24, 390-398.	1.8	100
154	Effect of Tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy. Modern Rheumatology, 2014, 24, 567-571.	1.8	10
155	Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2014, 66, 2675-2684.	5.6	290
156	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Modern Rheumatology, 2014, 24, 734-743.	1.8	11
157	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology, 2014, 24, 725-733.	1.8	12
158	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 715-724.	1.8	49
159	Lack of association betweenIL-15genetic variants and progression of joint destruction in Japanese patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 784-785.	0.9	8
160	Risk factors associated with the occurrence of distal radius fractures in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. Clinical Rheumatology, 2014, 33, 477-483.	2.2	19
161	Clinical Manifestations of Adultâ€Onset Still's Disease Presenting With Erosive Arthritis: Association With Low Levels of Ferritin and Interleukinâ€18. Arthritis Care and Research, 2014, 66, 642-646.	3.4	70
162	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	27.8	1,974

#	Article	IF	CITATIONS
163	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases, 2014, 73, 536-543.	0.9	82
164	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia [®] as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatology, 2014, 24, 754-762.	1.8	15
165	Effects of Smoking and Shared Epitope on the Production of Anti–Citrullinated Peptide Antibody in a Japanese Adult Population. Arthritis Care and Research, 2014, 66, 1818-1827.	3.4	61
166	Sites, frequencies, and causes of self-reported fractures in 9,720 rheumatoid arthritis patients: a large prospective observational cohort study in Japan. Archives of Osteoporosis, 2013, 8, 130.	2.4	20
167	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Modern Rheumatology, 2013, 23, 742-751.	1.8	28
168	<i>PLD4</i> as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis and Rheumatism, 2013, 65, 472-480.	6.7	62
169	Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. Clinical Immunology, 2013, 147, 71-78.	3.2	14
170	Two Susceptibility Loci to Takayasu Arteritis Reveal a Synergistic Role of the IL12B and HLA-B Regions in a Japanese Population. American Journal of Human Genetics, 2013, 93, 289-297.	6.2	136
171	Antiphospholipid Antibodies in Patients with Cutaneous Polyarteritis Nodosa and Livedo Vasculopathy. Journal of Dermatological Science, 2013, 69, e34.	1.9	1
172	Prevalence of and factors associated with vitamin D deficiency in 4,793 Japanese patients with rheumatoid arthritis. Clinical Rheumatology, 2013, 32, 1081-1087.	2.2	38
173	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24â€weeks. Annals of the Rheumatic Diseases, 2013, 72, 1488-1495.	0.9	51
174	Neuropsychiatric systemic lupus erythematosus: pathophysiology and the future of treatment. International Journal of Clinical Rheumatology, 2013, 8, 585-595.	0.3	0
175	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	3.5	146
176	Effect of Genetic Polymorphisms on Development of Gout. Journal of Rheumatology, 2013, 40, 1374-1378.	2.0	33
177	A Delphi Exercise to Identify Characteristic Features of Gout — Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. Journal of Rheumatology, 2013, 40, 498-505.	2.0	25
178	Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs. Journal of Rheumatology, 2013, 40, 1658-1668.	2.0	12
179	A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. Annals of the Rheumatic Diseases, 2013, 72, 310-312.	0.9	6
180	Methemoglobinemia Induced by Trimethoprim-Sulfamethoxazole in a Patient with Systemic Lupus Erythematosus. Internal Medicine, 2013, 52, 1741-1743.	0.7	9

#	Article	IF	CITATIONS
181	Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients. Modern Rheumatology, 2013, 23, 200-202.	1.8	5
182	Management of rheumatoid arthritis: the 2012 perspective. Modern Rheumatology, 2013, 23, 1-7.	1.8	32
183	Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Modern Rheumatology, 2013, 23, 788-793.	1.8	4
184	Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study. Modern Rheumatology, 2013, 23, 1179-85.	1.8	5
185	PADI4 and HLA-DRB1 Are Genetic Risks for Radiographic Progression in RA Patients, Independent of ACPA Status: Results from the IORRA Cohort Study. PLoS ONE, 2013, 8, e61045.	2.5	45
186	Serum antibodies against the 70k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study. Modern Rheumatology, 2013, 23, 71-80.	1.8	6
187	Major depressive disorder in patients with rheumatoid arthritis. Modern Rheumatology, 2013, 23, 237-244.	1.8	10
188	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Modern Rheumatology, 2013, 23, 742-751.	1.8	10
189	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology, 2013, 23, 945-952.	1.8	7
190	Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. Modern Rheumatology, 2013, 23, 1205-10.	1.8	9
191	A Genome-Wide Association Study Identified AFF1 as a Susceptibility Locus for Systemic Lupus Eyrthematosus in Japanese. PLoS Genetics, 2012, 8, e1002455.	3.5	115
192	Positive association betweenSTAT4polymorphisms and polymyositis/dermatomyositis in a Japanese population. Annals of the Rheumatic Diseases, 2012, 71, 1646-1650.	0.9	36
193	The Influence of Individual Joint Impairment on Functional Disability in Rheumatoid Arthritis Using a Large Observational Database of Japanese Patients. Journal of Rheumatology, 2012, 39, 476-480.	2.0	14
194	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Annals of the Rheumatic Diseases, 2012, 71, 817-824.	0.9	102
195	Quantitative effect of HLA-DRB1 alleles to ACPA levels in Japanese rheumatoid arthritis: no strong genetic impact of shared epitope to ACPA levels after stratification of HLA-DRB1*09:01. Annals of the Rheumatic Diseases, 2012, 71, 1095-1097.	0.9	19
196	Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-Î ³ . European Journal of Dermatology, 2012, 22, 668-671.	0.6	4
197	Performance of hands and feet radiographs in differentiation of psoriatic arthritis from rheumatoid arthritis. International Journal of Rheumatic Diseases, 2012, 15, 462-467.	1.9	15
198	Brief Report: Association of HLA–DRB1*0101/*0405 with susceptibility to anti–melanoma differentiation–associated gene 5 antibody–positive dermatomyositis in the Japanese population. Arthritis and Rheumatism, 2012, 64, 3736-3740.	6.7	78

#	Article	IF	CITATIONS
199	Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nature Genetics, 2012, 44, 511-516.	21.4	285
200	Frequency of Class III and IV Nephritis in Systemic Lupus Erythematosus Without Clinical Renal Involvement: An Analysis of Predictive Measures. Journal of Rheumatology, 2012, 39, 79-85.	2.0	89
201	Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation. Cytokine, 2012, 59, 252-257.	3.2	15
202	The increasing disease duration of patients at the time of orthopaedic surgery for rheumatoid arthritis. Rheumatology International, 2012, 32, 3323-3324.	3.0	5
203	ACPA-Negative RA Consists of Two Genetically Distinct Subsets Based on RF Positivity in Japanese. PLoS ONE, 2012, 7, e40067.	2.5	33
204	Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. Rheumatology International, 2012, 32, 749-757.	3.0	10
205	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatology International, 2012, 32, 1511-1519.	3.0	17
206	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatology International, 2012, 32, 1617-1624.	3.0	10
207	High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatology International, 2012, 32, 2057-2061.	3.0	28
208	Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatology International, 2012, 32, 361-366.	3.0	23
209	Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Modern Rheumatology, 2012, 22, 122-127.	1.8	19
210	Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Modern Rheumatology, 2012, 22, 209-215.	1.8	6
211	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology, 2012, 22, 327-338.	1.8	26
212	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Modern Rheumatology, 2012, 22, 498-508.	1.8	47
213	Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Modern Rheumatology, 2012, 22, 676-684.	1.8	7
214	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology, 2012, 22, 814-822.	1.8	21
215	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Modern Rheumatology, 2012, 22, 186-194.	1.8	2
216	A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Annals of the Rheumatic Diseases, 2011, 70, 2134-2139.	0.9	42

#	Article	IF	CITATIONS
217	Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. Rheumatology International, 2011, 31, 617-622.	3.0	23
218	Activation of the Activin A-ALK-Smad pathway in systemic sclerosis. Journal of Autoimmunity, 2011, 36, 181-188.	6.5	29
219	An Allopurinol-Controlled, Randomized, Double-Dummy, Double-Blind, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan. Journal of Clinical Rheumatology, 2011. 17. S13-S18.	0.9	51
220	Gout and hyperuricemia in young people. Current Opinion in Rheumatology, 2011, 23, 156-160.	4.3	46
221	Clinical and Radiological Features of Acute-Onset Diffuse Interstitial Lung Diseases in Patients with Rheumatoid Arthritis Receiving Treatment with Biological Agents: Importance of <i>Pneumocystis</i> Pneumonia in Japan Revealed by a Multicenter Study. Internal Medicine, 2011. 50. 305-313.	0.7	68
222	Clinical manifestations of neurological involvement in primary Sjögren's syndrome. Clinical Rheumatology, 2011, 30, 485-490.	2.2	96
223	Reparative radiological changes of a large joint after adalimumab for rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 591-592.	2.2	10
224	Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 1105-1111.	2.2	23
225	Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatology International, 2011, 31, 1487-1492.	3.0	83
226	Clinical images: Solitary extranodal malignant lymphoma of the forearm in rheumatoid arthritis. Arthritis and Rheumatism, 2011, 63, 304-304.	6.7	0
227	Anti 1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: A controlled study of 126 consecutive patients. Arthritis and Rheumatism, 2011, 63, 2436-2444.	6.7	59
228	NR2-reactive antibody decreases cell viability through augmentation of Ca2+ influx in systemic lupus erythematosus. Arthritis and Rheumatism, 2011, 63, 3952-3959.	6.7	27
229	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Annals of the Rheumatic Diseases, 2011, 70, 2148-2151.	0.9	166
230	Association ofEMCNwith Susceptibility to Rheumatoid Arthritis in a Japanese Population. Journal of Rheumatology, 2011, 38, 221-228.	2.0	8
231	Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study. Journal of Rheumatology, 2011, 38, 1585-1592.	2.0	75
232	Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1018-1029.	1.1	244
233	Incidence of falls and fear of falling in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 51-56.	1.8	21
234	The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Human Molecular Genetics, 2011, 20, 2680-2685.	2.9	90

#	Article	IF	CITATIONS
235	Comorbidities in Patients with Gout. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1045-1050.	1.1	17
236	Rapid Progressive Cerebral Atrophy in Systemic Lupus Erythematosus: Figure 1 Journal of Rheumatology, 2011, 38, 2689-2689.	2.0	3
237	Incidence of falls and fear of falling in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 51-56.	1.8	14
238	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatology, 2011, 21, 122-133.	1.8	52
239	Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Modern Rheumatology, 2011, 21, 223-227.	1.8	35
240	Interleukin-18 promoter polymorphisms in Japanese patients with rheumatoid arthritis: protective effect of the T allele and T/T genotype at rs360722. Modern Rheumatology, 2011, 21, 359-364.	1.8	5
241	Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Modern Rheumatology, 2011, 21, 296-301.	1.8	7
242	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 343-351.	1.8	51
243	Efficacy of total joint arthroplasty in patients with established rheumatoid arthritis: improved longitudinal effects on disease activity but not on health-related quality of life. Modern Rheumatology, 2011, 21, 476-481.	1.8	10
244	Studies of the efficacy and safety of methotrexate at dosages over 8Âmg/week using the IORRA cohort database. Modern Rheumatology, 2011, 21, 579-593.	1.8	10
245	Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Modern Rheumatology, 2011, 21, 594-597.	1.8	6
246	Increased HGF and c-Met in muscle tissues of polymyositis and dermatomyositis patients: Beneficial roles of HGF in muscle regeneration. Clinical Immunology, 2010, 136, 387-399.	3.2	14
247	Clinical Images: Dramatic amelioration of pneumatosis cystoides intestinalis in systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 1468-1468.	6.7	2
248	A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nature Genetics, 2010, 42, 515-519.	21.4	241
249	Human Sodium Phosphate Transporter 4 (hNPT4/SLC17A3) as a Common Renal Secretory Pathway for Drugs and Urate. Journal of Biological Chemistry, 2010, 285, 35123-35132.	3.4	128
250	Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Annals of the Rheumatic Diseases, 2010, 69, 1232-1234.	0.9	61
251	Association between GLUT9 and gout in Japanese men. Annals of the Rheumatic Diseases, 2010, 69, 932-933.	0.9	34
252	Opinions of Japanese rheumatology physicians regarding clinical practice guidelines. International Journal for Quality in Health Care, 2010, 22, 78-85.	1.8	9

#	Article	IF	CITATIONS
253	Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Modern Rheumatology, 2010, 20, 46-53.	1.8	19
254	Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Modern Rheumatology, 2010, 20, 46-53.	1.8	15
255	Multiple extensor tendon ruptures caused by tophaceous gout. Modern Rheumatology, 2010, 20, 210-212.	1.8	11
256	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Modern Rheumatology, 2010, 20, 280-286.	1.8	42
257	Single nucleotide polymorphisms of CD244 gene predispose to renal and neuropsychiatric manifestations with systemic lupus erythematosus. Modern Rheumatology, 2010, 20, 427-431.	1.8	15
258	Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention. Modern Rheumatology, 2010, 20, 452-457.	1.8	13
259	Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis. Modern Rheumatology, 2010, 20, 466-470.	1.8	12
260	Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Modern Rheumatology, 2010, 20, 478-485.	1.8	10
261	Bone erosion of the sternocostal joint in a patient with Behcet's disease. Japanese Journal of Clinical Immunology, 2009, 32, 186-188.	0.0	1
262	Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. Journal of Rheumatology, 2009, 36, 898-906.	2.0	167
263	The Influence of Sex on Patients with Rheumatoid Arthritis in a Large Observational Cohort. Journal of Rheumatology, 2009, 36, 508-511.	2.0	56
264	Human osteoclastogenic T cells and human osteoclastology. Arthritis and Rheumatism, 2009, 60, 3158-3163.	6.7	27
265	Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients. Journal of Bone and Mineral Metabolism, 2009, 27, 574-583.	2.7	22
266	Successful treatment for sympathetic storms in a patient with neuro-Behçet's disease. Clinical Rheumatology, 2009, 28, 357-359.	2.2	8
267	Associated factors for falls and fear of falling in Japanese patients with rheumatoid arthritis. Clinical Rheumatology, 2009, 28, 1325-1330.	2.2	61
268	T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis. Bone, 2009, 45, 627-639.	2.9	17
269	Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Modern Rheumatology, 2009, 19, 379-383.	1.8	11
270	A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. Modern Rheumatology, 2009, 19, 140-146.	1.8	11

#	Article	IF	CITATIONS
271	Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome. Modern Rheumatology, 2009, 19, 437-440.	1.8	39
272	Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Modern Rheumatology, 2009, 19, 379-383.	1.8	11
273	The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis. Modern Rheumatology, 2009, 19, 643-651.	1.8	9
274	Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine. Modern Rheumatology, 2009, 19, 681-686.	1.8	5
275	Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study. Journal of Bone and Mineral Metabolism, 2008, 26, 499-505.	2.7	28
276	Return of infliximab efficacy after total knee arthroplasty in a patient with rheumatoid arthritis. Clinical Rheumatology, 2008, 27, 549-550.	2.2	10
277	Risk factors for wrist surgery in rheumatoid arthritis. Clinical Rheumatology, 2008, 27, 1387-1391.	2.2	10
278	Molecular aspects of rheumatoid arthritis: role of transcription factors. FEBS Journal, 2008, 275, 4463-4470.	4.7	76
279	Therapeutic Effects of Alendronate on Bone Erosion and Atrophy in a Patient with Rheumatoid Arthritis and Hepatitis C Virus Infection. Journal of Rheumatology, 2008, 35, 2284-2286.	2.0	5
280	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Modern Rheumatology, 2008, 18, 146-152.	1.8	43
281	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology, 2008, 18, 447-454.	1.8	29
282	Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Annals of the Rheumatic Diseases, 2007, 66, 407-409.	0.9	340
283	Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. Journal of Human Genetics, 2007, 52, 557-560.	2.3	27
284	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Modern Rheumatology, 2007, 17, 28-32.	1.8	46
285	Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Modern Rheumatology, 2007, 17, 98-105.	1.8	29
286	Nonsteroidal anti-inflammatory drug use does not affect short-term endoscopic and histologic outcomes after Helicobacter pylori eradication in patients with rheumatoid arthritis. Modern Rheumatology, 2007, 17, 228-234.	1.8	4
287	Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Modern Rheumatology, 2007, 17, 283-289.	1.8	42
288	Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Modern Rheumatology, 2007, 17, 403-408.	1.8	23

#	Article	IF	CITATIONS
289	Risk factors for total knee arthroplasty in rheumatoid arthritis. Modern Rheumatology, 2007, 17, 476-480.	1.8	15
290	Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. Journal of Rheumatology, 2007, 34, 303-10.	2.0	43
291	Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. Journal of Rheumatology, 2007, 34, 964-8.	2.0	54
292	MHC2TA is associated with rheumatoid arthritis in Japanese patients. Annals of the Rheumatic Diseases, 2006, 66, 274-275.	0.9	25
293	Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Modern Rheumatology, 2006, 16, 75-76.	1.8	40
294	Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Modern Rheumatology, 2006, 16, 151-157.	1.8	28
295	Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Modern Rheumatology, 2006, 16, 214-219.	1.8	12
296	One third of Japanese patients with rheumatoid arthritis use complementary and alternative medicine. Modern Rheumatology, 2006, 16, 355-359.	1.8	14
297	Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Modern Rheumatology, 2006, 16, 376-380.	1.8	16
298	Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. Modern Rheumatology, 2006, 16, 327-329.	1.8	1
299	Failure to confirm association betweenSLC22A4 polymorphism and rheumatoid arthritis in a Japanese population. Arthritis and Rheumatism, 2005, 52, 2947-2948.	6.7	13
300	Prevalence of Helicobacter pylori infection and risk of upper gastrointestinal ulcer in patients with rheumatoid arthritis in Japan. Modern Rheumatology, 2005, 15, 340-345.	1.8	16
301	Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Modern Rheumatology, 2005, 15, 323-328.	1.8	29
302	Outcome measures for acute and chronic gout. Journal of Rheumatology, 2005, 32, 2452-5.	2.0	52
303	Identification of Two Novel Mutations in Adenine Phosphoribosyltransferase Gene in Patients with 2,8â€Đihydroxyadenine Urolithiasis. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1141-1145.	1.1	5
304	Familial juvenile hyperuricemic nephropathy: Detection of mutations in the uromodulin gene in five Japanese families. Kidney International, 2004, 65, 1589-1597.	5.2	60
305	A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis and Rheumatism, 2004, 51, 321-325.	6.7	356
306	Cartilage oligomeric matrix protein in serum and synovial fluid of rheumatoid arthritis: potential use as a marker for joint cartilage damage. Modern Rheumatology, 2004, 14, 356-360.	1.8	8

#	Article	IF	CITATIONS
307	Spinal tophaceous gout mimicking a spinal tumor. Journal of Rheumatology, 2004, 31, 1459-60.	2.0	13
308	Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis and Rheumatism, 2003, 49, 784-788.	6.7	206
309	Angiogenesis and Its Therapeutic Implication 2. Rheumatoid Arthritis and Angiogenesis. Internal Medicine, 2003, 42, 297-299.	0.7	1
310	Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. Journal of Rheumatology, 2003, 30, 1157-63.	2.0	38
311	A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus. Journal of Rheumatology, 2003, 30, 2369-73.	2.0	19
312	Aconitine facilitates spontaneous transmitter release at rat ventromedial hypothalamic neurons. British Journal of Pharmacology, 2002, 135, 816-822.	5.4	22
313	Comparison of the Rau method and the Larsen method in the evaluation of radiographic progression in early rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 682-7.	2.0	4
314	The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. Journal of Rheumatology, 2002, 29, 1950-3.	2.0	100
315	Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. Journal of Rheumatology, 2002, 29, 2492-9.	2.0	61
316	Progressive Appearance of Overlap Syndrome Together with Autoantibodies in a Patient with Fatal Thrombotic Microangiopathy. American Journal of the Medical Sciences, 2000, 320, 348-351.	1.1	15
317	Does hyperuricemia aeffect mortality? A prospective cohort study of Japanese male workers Journal of Epidemiology, 2000, 10, 403-409.	2.4	202
318	A germline mutation abolishing the original stop codon of the human adenine phosphoribosyltransferase (APRT) gene leads to complete loss of the enzyme protein. Human Genetics, 1998, 102, 197-202.	3.8	18
319	Radiation Dosimetry Measurements with Real Time Radiation Monitoring Device (RRMD)-II in Space Shuttle STS-79. Japanese Journal of Applied Physics, 1997, 36, 7453-7459.	1.5	8
320	Intervention of somatic mutational events in vivo by a germline defect at the adenine phosphoribosyltransferase locus. Human Genetics, 1997, 99, 164-170.	3.8	3
321	Relationship between LET and RBE values for Escherichia coli determined using carbon ion beams from the TIARA cyclotron and HIMAC synchrotron Journal of General and Applied Microbiology, 1997, 43, 175-177.	0.7	7
322	Interaction between the intracellular Ca2+ stores in rat dissociated hippocampal neurones. NeuroReport, 1996, 7, 1421-1426.	1.2	11
323	The origin of the most common mutation of adenine phosphoribosyltransferase among Japanese goes back to a prehistoric era. Human Genetics, 1996, 98, 596-600.	3.8	17
324	Selection against blood cells deficient in hypoxanthine phosphoribosyltransferase (HPRT) in Lesch-Nyhan heterozygotes occurs at the level of multipotent stem cells. Human Genetics, 1995, 96, 674-680.	3.8	23

#	Article	IF	CITATIONS
325	Differential cytotoxic effects of mizoribine and its aglycone on human and murine cells and on normal and enzyme-deficient human cells. Biochemical Pharmacology, 1995, 50, 1099-1102.	4.4	9
326	Adenine phosphoribosyltransferase deficiency identified by urinary sediment analysis: cellular and molecular confirmation. Clinical Genetics, 1995, 48, 246-250.	2.0	12
327	Identification of Commonly Recognized Epitopes on a Rare Autoantigen: Poly(ADP-ribose) Polymerase. Clinical Immunology and Immunopathology, 1994, 73, 290-295.	2.0	4
328	Molecular Basis for the Interaction between Human IgM and Staphylococcal Protein A. Clinical Immunology and Immunopathology, 1994, 72, 394-401.	2.0	24
329	Physiological roles of glycine and γ-aminobutyric acid in dissociated neurons of rat visual cortex. Brain Research, 1994, 640, 229-235.	2.2	8
330	Sjögren''s Syndrome in One of Two Sisters with Idiopathic Renal Hypouricemia. Internal Medicine, 1994, 33, 505-511.	0.7	1
331	Formation of DNA strand breaks by D-penicillamine and bucillamine in human lymphocytes. Immunopharmacology, 1993, 26, 113-118.	2.0	9
332	Novel Ca2+ currents in mammalian CNS neurons. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1992, 16, 943-957.	4.8	2
333	Accelerated purine nucleotide degradation by anaerobic but not by aerobic ergometer muscle exercise. Metabolism: Clinical and Experimental, 1992, 41, 364-369.	3.4	47
334	Phosphoribosylpyrophosphate synthetase in human erythrocytes: Assay and kinetic studies using high-performance liquid chromatography. Clinica Chimica Acta, 1991, 203, 143-152.	1.1	9
335	A new method for the determination of adenine phosphoribosyltransferase activity in human erythrocytes by reversed phase high performance liquid chromatography. Biomedical Chromatography, 1991, 5, 57-61.	1.7	2
336	Identification of a compound heterozygote for adenine phosphoribosyltransferase deficiency (APRT*J/APRT*Q0) leading to 2,8-dihydroxyadenine urolithiasis. Human Genetics, 1990, 85, 500-4.	3.8	16
337	Poly(ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD+. Biochemical and Biophysical Research Communications, 1989, 163, 1113-1118.	2.1	13
338	Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Advances in Enzyme Regulation, 1988, 27, 395-404.	2.6	54
339	Screening for adenine and hypoxanthine phosphoribosyltransferase deficiencies in human erythrocytes by high-performance liquid chromatography. Clinica Chimica Acta, 1987, 170, 281-289.	1.1	21
340	Evaluation of the Severity of Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency Using Viable T Cells. Human Heredity, 1985, 35, 358-363.	0.8	5
341	Severe impairment in adenine metabolism with a partial deficiency of adenine phosphoribosyltransferase. Metabolism: Clinical and Experimental, 1985, 34, 164-168.	3.4	52
342	Dihydroxyadenine Urolithiasis in Children with Partial Deficiency of Adenine Phosphoribosyltransferase. Urologia Internationalis, 1981, 36, 274-280.	1.3	21